Abstract
The aims of this study were to examine prognostic significance of pigment epithelium-derived factor (PEDF) in patients with stage IA-IIIB non-small cell lung cancer (NSCLC). Using immunohistochemistry and multivariate analysis, we set out to investigate whether PEDF expression could provide prognostic information in NSCLC in a cohort of 69 patients who had undergone radical resection for NSCLC. The correlation between PEDF and the clinical pathological features of stage I-III NSCLC after radical surgery were analyzed as well as influence on long term survival. No correlation between PEDF intensity, PEDF area or PEDF area index and clinic opathologic parameters was seen. PEDF values showed a slight correlation to the tumor stage. There was a significant negative correlation (T = -0.288, p = 0.002) between pathologic T-stage and median PEDF area and vice versa a positive correlation (T = 0.227, p = 0.016) with median PEDF intensity. We could not detect any correlation between PEDF and long term survival. For PEDF analysis, there was only a slight correlation between expression and T-stage of the tumor.
Highlights
Non-small-cell lung cancer (NSCLC) is one of the most common cancers worldwide#Alexander Emmert and Angelika Oellerich contributed to this work. †Hanibal Bohnenberger and Bernhard C
A total of 69 patients with available non-small cell lung cancer (NSCLC) tumor tissue blocks were included in the analysis
Lung cancer related death occurred in 33 patients (47.8%); for unknown reasons in 6 (8.7%), due to a secondary tumor in 1 (1.5%), and for other non-tumorous reasons in 4 patients (5.8%)
Summary
Non-small-cell lung cancer (NSCLC) is one of the most common cancers worldwide#Alexander Emmert and Angelika Oellerich contributed to this work. †Hanibal Bohnenberger and Bernhard C. Non-small-cell lung cancer (NSCLC) is one of the most common cancers worldwide. #Alexander Emmert and Angelika Oellerich contributed to this work. With the recent advances in screening, diagnosis, and treatment of this disease, guidelines are constantly being reviewed to provide the best in detection and therapy. The new TNM classification for lung cancer is being proposed by the International Association for the Study of Lung Cancer (IASLC), and the 8th edition of TNM staging system is expected to be released in 2016 [1]. Especially for early stage NSCLC, prognostic biomarkers are still lacking
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
